Substance / Medication

Benznidazole

Overview

Active Ingredient
benznidazole
RxNorm CUI
18994

Indications

Trypanosoma cruzi Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by. 14 T. cruzi [see Clinical Studies ()] This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of. Continued approval for this indication may be contingent upon verification and description of clinical benef

Labeler: Exeltis USA, Inc.Updated: 2025-09-15T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Mechanisms of resistance of Trypanosoma cruzi to benznidazole and nifurtimox: Molecular implications and multifaceted impact.
Ochoa-Martínez Paulina, López-Domínguez Jaime, López-Monteon Aracely et al. · Acta Trop · 2026
PMID: 41365456Meta-Analysis
Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.
Crespillo-Andújar Clara, Comeche Belén, Hamer Davidson H et al. · PLoS Negl Trop Dis · 2022
PMID: 35576215Meta-AnalysisFull text (PMC)
In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis.
Vela Andrea, Coral-Almeida Marco, Sereno Denis et al. · PLoS Negl Trop Dis · 2021
PMID: 33750958Meta-AnalysisFull text (PMC)
Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.
Frade Virgínia Paula, Simões Nathália Soares, Couto Nayara Ragi Baldoni et al. · Rev Inst Med Trop Sao Paulo · 2020
PMID: 32725057Meta-AnalysisFull text (PMC)
Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
Ciapponi Agustín, Barreira Fabiana, Perelli Lucas et al. · PLoS Negl Trop Dis · 2020
PMID: 32804966Meta-AnalysisFull text (PMC)
Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.
Crespillo-Andújar Clara, Venanzi-Rullo Emmanuele, López-Vélez Rogelio et al. · Drug Saf · 2018
PMID: 30006773Meta-Analysis
Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.
Wiens Matthew O, Kanters Steve, Mills Edward et al. · Antimicrob Agents Chemother · 2016
PMID: 27550362Meta-AnalysisFull text (PMC)
Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.
Pérez-Molina José A, Pérez-Ayala Ana, Moreno Santiago et al. · J Antimicrob Chemother · 2009
PMID: 19819909Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Benznidazole (substance)
SNOMED CT
714091003
UMLS CUI
C0053230
RxNorm CUI
18994
Labeler
Exeltis USA, Inc.

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.